

Declarations of potential conflicts of interest of the Cochrane Airways Group

September 2010

The Cochrane Steering Group recommends that Review Group members of influence (editorial board and editorial base staff) should declare financial support for their research interests, clinical practice (if relevant), stocks, legal advice, consultancies, involvement in primary research in the subject area of their review group, and any other 'competing interests' that they judge relevant. A conflict of interest exists when a secondary interest (e.g. personal financial gain) can influence, or have the appearance of influencing, judgements regarding the primary interest. Disclosing a conflict of interest is not meant to discourage involvement in outside activities, or receipt of support for an individual's scientific work from commercial sources. Disclosure is designed to maintain the scientific and professional integrity of the Cochrane Airways Group. Each member of the Editorial and Advisory Board and all scientific/professional personnel working with the editorial office must complete and sign this form each year.

A. Financial interests

In the **last five years**, have you:

1. Received research funding: any grant, contract or gift, commissioned research, or fellowship from a related organisation to conduct research? If yes, list.
2. Had paid consultancies: any paid work, consulting fees (in cash or kind) for an organisation related to the scope of the airways group? If yes, list.
3. Received honoraria: one-time payments (in cash or kind) from a related organisation related to the scope of the airways group? If yes, list.
4. Do you hold or have you applied for a patent on a treatment for any form of airways treatment?
4. Served as a director, officer, partner, trustee, employee or held a position of management with an organisation related to the scope of the airways group? If yes, list.
5. Possessed share-holdings, stock, stock options, equity with a related organisation related to the scope of the airways group (excludes mutual funds or similar arrangements where the individual has no control over the selection of the shares)? If yes, list.
6. Received personal gifts from an organisation related to the scope of the airways group? If yes, list.
7. Had an outstanding loan with an organisation related to the scope of the airways group? If yes, list.
8. Received royalty payments from a related organisation? If yes, list.

B. Non-financial interests

Do you have any other competing interests that could pose a conflict of interest that might reasonably appear to be related to the scope of the airways group? If yes, explain.

Editorial Base Staff

Elizabeth Arnold	None declared.
Chris Cates	None declared.
Charlotta Karner	Received funding for a PhD in basic research in asthma at King's College London from Novartis (2005-2009).
Emma Welsh	None declared.

Editorial Board

Anne Chang	Received grants from government (NHMRC, NIH, Queensland Government, Northern Territories government, research bodies (RCH Foundation, Telstra Foundation, Financial markets research grant) and not for profit organisations (Queensland Asthma Foundation).
Francine Ducharme	Received research funding from GlaxoSmithKline and Merck & Co, USA and received support for a patient database from Merck Canada and Nycomed.
Peter Gibson	Is the principle investigator on projects funded by NHMRC Australia, University of Newcastle, Hunter Medical Research Institute and GlaxoSmithKline. Peter received honoraria for European Respiratory Society, AAAAI, ATS, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Pharmaxis.
Mike Greenstone	Received sponsorship from GSK to attend the European Respiratory Society on a couple of occasions in the last 5 years.
Anne Holland	Received research funding from National Health and Medical Research Council Australia, Caulfield Research Trust, Winston Churchill Memorial Trust, Telstra, Institute for Breathing and Sleep, Alfred Research Trust, National Stroke Foundation, Windermere Foundation Limited, La Trobe University, National Trauma Research Institute, Physiotherapy Research Foundation, Victorian Tuberculosis and the Lung Foundation. Anne was paid as a consultant for Australian Unity and received honoraria for Bayer Pharmaceuticals and, Boehringer Ingelheim
Paul Jones	Received consulting fees from AstraZeneca, GlaxoSmithKline. Novartis and Hoffman-LaRoche, speaking fees from AstraZeneca and GlaxoSmithKline and grant support from Boehringer Ingelheim and GlaxoSmithKline.
Toby Lasserson	None declared.

Phillippa Poole	None declared.
Brian Rowe	Received research funding from Merck, was paid enrolment fees for participation in a clinical trial sponsored by MedImmune and a clinical trial sponsored by GSK. Brian also received honoraria payment from GSK for asthma CME lectures only in 2009 and 2010 and honoraria payment for asthma CME lectures from AstraZeneca in 2006.
Haydn Walters	Has taken part in collaborative clinical pharmacology studies with a number of pharmaceutical companies including GlaxoWellcome, Astra Zeneca, Pfizer, Boehringer, Schering Plough, SKB and Novartis. He has, in the past, held consultancies with GlaxoWellcome, Pfizer and AstraZeneca. He has received honoraria from a number of the companies listed over the past 15 years.
John White	Has been involved in consultancy for GlaxoSmithKline and Nycomed and given educational presentations to healthcare professionals from AstraZeneca, GlaxoSmithKline, Pfizer and Boehringer Ingelheim.
Richard Wood-Baker	Received financial support through enrolling subjects in sponsored clinical research trials (university grant monies, NH&MRC, Department of Health & Aged Care, Royal Hobart Hospital Research Foundation), sponsored research (Ciba-Geigy/Novartis, ICI pharmaceuticals, Pharmacia & Upjohn, Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi-Synthelabo, GlaxoSmithKline, Gilead) and received unrestricted research funding from pharmaceutical companies (GlaxoSmithKline). Richard received honoraria for presentations to health professionals and expenses related to clinical trials or presentations.
John Wright	None declared.